By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) said Wednesday that a phase 3 trial of its Breztri Aerosphere treatment of chronic obstructive pulmonary disease had met its primary objective.

The pharmaceutical company said that in the Ethos trial, Breztri Aerosphere showed a statistically significant reduction in symptoms when compared with the standard recommended therapies for COPD.

Breztri Aerosphere is a combination of three different drugs and was being compared to dual-combination therapies.

The treatment has been approved in Japan, and is under review in China, the U.S. and Europe.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

August 28, 2019 02:26 ET (06:26 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca